<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23313">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814813</url>
  </required_header>
  <id_info>
    <org_study_id>A071101</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>NCI-2013-00444</secondary_id>
    <nct_id>NCT01814813</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery</brief_title>
  <official_title>A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agenus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: NCI Central Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well giving vaccine therapy with or without
      bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be
      removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a
      person's own tumor tissue may help the body build an effective immune response to kill tumor
      cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block
      tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
      Others find tumor cells and help kill them. It is not yet known whether giving vaccine
      therapy is more effective with or without bevacizumab in treating glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the effects of a vaccine with bevacizumab versus
      bevacizumab alone on a patient's brain tumor. The vaccine is called heat shock protein
      peptide complex 96 (HSPPC-96). HSPPC-96 is experimental.   Specifically, HSPPC-96 is a
      protein that may work to help the body have a response against remaining brain tumor cells.
       Bevacizumab has been approved by the Food and Drug administration for treating brain tumors
      that grow back.  In this study, patients will either get HSPPC-96 vaccine at the same time
      as bevacizumab, HSPPC vaccine first and then bevacizumab if the tumor comes back, or
      bevacizumab alone. The use of HSPPC-96 and bevacizumab is investigational.

      The primary objective of the study is to determine whether there is an overall survival
      advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of
      progression, in comparison with bevacizumab alone in patients with surgically resectable
      recurrent glioblastoma multiforme.

      The secondary objectives are:

        1. to evaluate the safety and tolerability of HSPPC-96 with bevacizumab

        2. to evaluate the progression free survival of HSPPC-96 with bevacizumab, given
           concomitantly or at the point of progression.

      Patients must undergo surgery within 28 days from pre-registration. Upon confirmation of
      adequacy of tissue for vaccine manufacture and ≥ 90% resection by central radiology review,
      patients will be randomized to one of three treatment arms. Please see the &quot;Arms&quot; section
      for more details.

      Patients will be monitored approximately 6.5 years post surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 6.5 years post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 6.5 years post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Arm 1, HSPPC-96 + concomitant bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression.  (1 cycle=14 days) HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion.
Note:  If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2, HSPPC-96 with bevacizumab at progression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression.  (1 cycle = 14 days)
NOTE:  It is possible that HSPPC-96 vaccination may end prior to evidence of progression.  In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3, Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSPPC-96</intervention_name>
    <description>intradermal administration</description>
    <arm_group_label>Arm 1, HSPPC-96 + concomitant bevacizumab</arm_group_label>
    <arm_group_label>Arm 2, HSPPC-96 with bevacizumab at progression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Arm 1, HSPPC-96 + concomitant bevacizumab</arm_group_label>
    <arm_group_label>Arm 2, HSPPC-96 with bevacizumab at progression</arm_group_label>
    <arm_group_label>Arm 3, Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pre-registration (Pre-Surgery) Eligibility Criteria

          -  Histologic documentation:  Prior histologic diagnosis of GBM at first occurrence.

          -  Stage: First or second recurrence of GBM considered to be surgically resectable.

          -  Prior Treatment:

               -  No radiotherapy within 90 days prior to pre-registration.

               -  No prior treatment with any anti-angiogenic agent targeting the VEGF pathway
                  including but not limited to bevacizumab, cediranib, vandetanib,
                  sunitinib,pazopanib, aflibercept, or sorafenib

               -  No prior treatment with HSPPC-96 or other investigational immunotherapy.

               -  Must have received prior treatment with radiotherapy and temozolomide for
                  histologically confirmed GBM at initial diagnosis.

               -  No tumor directed therapy for most recent progression.

               -  No prior Gliadel® wafers.

          -  No clinically significant cardiovascular disease:

               -  Patients with a history of hypertension must be well controlled (&lt;150/90) on a
                  regimen of antihypertensive therapy.

               -  History of arterial thrombotic events within the past 6 months, including
                  transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral
                  arterial thrombus, unstable angina or angina requiring surgical or medial
                  intervention in the past 6 months, or myocardial infarction (MI).  Patients with
                  clinically significant peripheral artery disease (i.e., claudication on less
                  than one block), significant vascular disease (i.e., aortic aneurysm, history of
                  aortic dissection) are not eligible.

               -  Patients who have had a deep vein thrombosis or pulmonary embolus within the
                  past 6 months are eligible if they are on stable therapeutic anticoagulation

               -  No current New York Heart Association classification II, III or IV congestive
                  heart failure

          -  No significant bleeding within the past 6 months; no bleeding diathesis or
             coagulopathy

          -  No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within past 12 months

          -  No evidence of any systemic autoimmune disease (e.g. Hashimoto's thyroiditis) and/or
             any history of primary or secondary immunodeficiency, and no immunosuppressant
             therapy (with the exception of dexamethasone as noted below) for any reason

          -  Age ≥ 18 years of age

          -  Karnofsky functional status rating ≥70

          -  No more than 16 mg dexamethasone (or equivalent) per day

          -  Non-pregnant and non-nursing

        Registration (Post-Surgery) Eligibility Criteria

          -  Pre-registration eligibility criteria continue to be met

          -  Histologic documentation: confirmed histological diagnosis of recurrent GBM

          -  ≥ 90% surgical resection of recurrent GBM confirmed by central radiology review by
             MRI with or without gadolinium per institutional guidelines.  A CT scan is allowable
             in place of MRI only in situations where an MRI is contraindicated (e.g., patient has
             a heart pacemaker, metallic devices in the eye, brain or spine, severe
             claustrophobia).

          -  ≥ 9 grams of resected tumor available for vaccine manufacture as determined by
             institutional pathologist

          -  Availability of ≥ 6 clinical vials of HSPPC-96

          -  Required Initial Laboratory Values:

               -  Granulocytes ≥1,500/µL

               -  Platelet count ≥100,000/µL

               -  Total Bilirubin     ≤ 2.0 x ULN

               -  UPC ratio           &lt;1 OR

               -  Urine protein       ≤ 1+

               -  Calculated creatinine clearance      ≥45 ml/min

               -  SGOT/SGPT(AST/ALT) ≤ 2.5 x ULN

          -  No serious, non-healing wounds or ulcers

          -  At least 7 days since any minor surgery such as port placement

          -  No major surgical procedures, open biopsy or significant traumatic injury ≤ 28 days
             prior to registration or anticipation of need for elective or planned major surgical
             procedure during the study. Core biopsy or other minor surgical procedures ≤7 days
             prior to registration.

          -  No active or recent hemoptysis (≥½ teaspoon of bright red blood per episode)≤30 days
             prior to registration.

          -  No new bleeding on D28 (+/3) MRI (or CT if MRI is contraindicated)

          -  No clinical deterioration at the time of registration/randomization

          -  If a second surgery is needed for completion of resection, this should be within 30
             days from the first surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Parsa, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California at San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco - Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Parsa</last_name>
      <phone>415-514-9401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atif Hussein, M.D.</last_name>
      <phone>954-986-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Komotar, M.D.</last_name>
      <phone>305-243-4200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Nicholas, M.D.</last_name>
      <phone>773-834-9026</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Raizer, M.D.</last_name>
      <phone>312-503-4724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Aiken, M.D.</last_name>
      <phone>312-942-2388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evanston CCOP North Shore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Merrell, M.D.</last_name>
      <phone>847-570-2570</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, MD</last_name>
      <phone>816-823-0555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's South Hospital</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, M.D.</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City CCOP</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, M.D.</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Curry, M.D.</last_name>
      <phone>617-726-3779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Curry, M.D.</last_name>
      <phone>617-726-3779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Cancer Research Consortium Community Clinical Oncology Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tareq Al Baghdadi, M.D.</last_name>
      <phone>734-712-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Parney, M.D.</last_name>
      <phone>507-284-8167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centerpoint Medical Center LLC</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, M.D.</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Kaur, M.D.</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Hematology and Oncology Associates Incorporated</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, M.D.</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Hematology Oncology Associates, Incorporated</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, MD</last_name>
      <phone>816-823-0555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, MD</last_name>
      <phone>816-823-0555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's East - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, MD</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liberty Radiation Oncology Clinic</name>
      <address>
        <city>Liberty</city>
        <state>Missouri</state>
        <zip>64068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, M.D.</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Oncology, Incorporated</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur, MD</last_name>
      <phone>913-948-5588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tran</last_name>
      <phone>314-747-7509</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Shonka, M.D.</last_name>
      <phone>402-559-5520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilo Fadul, M.D.</last_name>
      <phone>603-650-6312</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Goldlust, M.D.</last_name>
      <phone>551-996-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Bruce, M.D.</last_name>
      <phone>212-305-7346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Curry, M.D.</last_name>
      <phone>513-558-0863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Sloan, M.D.</last_name>
      <phone>216-844-6054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Pointe</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Curry, M.D.</last_name>
      <phone>513-558-0863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Kurkjian, M.D.</last_name>
      <phone>405-271-8777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Kurkjian, M.D.</last_name>
      <phone>405-271-8777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Oncology Research Consortium</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Conlin</last_name>
      <phone>503-216-6300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute - University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Colman</last_name>
      <phone>801-585-0270</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
